Scarica l'app Stockscreener
5.40
9.85%
-0.59
Precedente Chiudi:
$5.99
Aprire:
$5.82
Volume 24 ore:
99,855
Relative Volume:
1.65
Capitalizzazione di mercato:
$9.44M
Reddito:
$102.80K
Utile/perdita netta:
$-5.32M
Rapporto P/E:
-1.4211
EPS:
-3.8
Flusso di cassa netto:
$-5.45M
1 W Prestazione:
+13.92%
1M Prestazione:
+133.26%
6M Prestazione:
+69.65%
1 anno Prestazione:
+25.58%
Intervallo 1D:
$5.26
$5.97
Intervallo di 1 settimana:
$4.50
$6.90
Portata 52W:
$1.957
$10.28
Creative Medical Technology Holdings Inc Stock (CELZ) Company Profile
Nome
Creative Medical Technology Holdings Inc
Settore
Industria
Telefono
480-399-2822
Indirizzo
211 E. OSBORN RD., PHOENIX
Confronta CELZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CELZ
Creative Medical Technology Holdings Inc
|
5.40 | 9.44M | 102.80K | -5.32M | -5.45M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Creative Medical Technology Holdings Inc Borsa (CELZ) Ultime notizie
Allworth Financial LP Raises Stake in Align Technology, Inc. (NASDAQ:ALGN) - Defense World
Creative medical technology director Michael Finger sells $8,062 in stock - Investing.com
Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential - The Manila Times
Aterian Issues Letter to Shareholders - The Manila Times
This Groundbreaking Fertility Treatment Could Make IVF ObsoleteNew Presidential Order Accelerates Access - StockTitan
Roth Capital Has Negative Outlook for CELZ FY2028 Earnings - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Creative Medical Technology Reports Mid-Term Data Showing Reduced Opioid Use With StemSpine - Nasdaq
Creative Medical Technology rises on positive data for stem cell therapy - TradingView
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - The Manila Times
Fortis Inc. Files 2024 Year-End Disclosure Documents - The Manila Times
Revolutionary Back Pain Therapy Frees 90% of Patients from Opioid Dependency in Landmark Study - StockTitan
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose - Patient Care Online
Mergers & Acquisitions Tracker - Plastics News
Creative Medical reports progress in Type 2 Diabetes treatment - MSN
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
EGenesis Deems Second Transplant of Genetically Modified Porcine Kidney EGEN-2784 Successful - CGTLive™
Investigational Cell Therapy Cuts Insulin Dependency in Late-Stage Type 2 Diabetes - Patient Care Online
Creative Medical Technology’s Cell Therapy AlloStem Reduces Insulin Dependency in Late-Stage Type 2 Diabetes - CGTLive™
Creative Medical reports progress in Type 2 Diabetes treatment By Investing.com - Investing.com Australia
CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes - MD Magazine
Creative Medical Technology's CELZ-201 Shows 80% Efficacy In Type 2 Diabetes Trial - Nasdaq
Aspirin, NSAID Use Linked to Lower Cancer, Mortality Risk in Chronic Liver Diseases - MD Magazine
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - The Manila Times
Revolutionary Diabetes Breakthrough: CELZ's AlloStem™ Slashes Insulin Dependency in Clinical Trial - StockTitan
In Food Allergy, Exposure to Store-Bought Peanut Butter Bests Avoidance Strategies - MD Magazine
BLA Submission Planned for CORDStrom in RDEB - MD Magazine
Clinical Quiz: Diagnosis and Biomarkers in Anaphylaxis - MD Magazine
Long-Term VIVID-2 Data for Mirikizumab in Crohn’s Disease, with Edward Barnes, MD, MPH - MD Magazine
Nerandomilast Meets Primary Endpoint in Improving FVC in Progressive Pulmonary Fibrosis - MD Magazine
Trading Update: Ford Motor Co (F) Stock Endures 2.56% Monthly Volatility - The News Heater
PDD Holdings Inc ADR (PDD) Shares Rise Despite Market Challenges - The News Heater
Creative Medical enhances diabetes treatment with AI tech - MSN
Creative Medical Technology Holdings (CELZ): AI-Enhanced Stem Cell Therapy for Diabetes - Insider Monkey
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz - EIN News
Creative Medical enhances diabetes treatment with AI tech By Investing.com - Investing.com South Africa
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - The Manila Times
Breakthrough: AI Accelerates Diabetes Cure Research as Creative Medical Doubles Development Speed - StockTitan
EvokAI Creative Labs Sets Date for Share Consolidation - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Nisa Investment Advisors LLC Acquires 4,234 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) - Defense World
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - The Manila Times
Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from - EIN News
Revolutionary Stem Cell Therapy Tackles Chronic Back Pain: First Trial Results Unveiled - StockTitan
La Rosa Holdings Corp. Appoints Commercial Real Estate Veteran JM Padron to Lead National Expansion of - EIN News
Odyssey Trust Company Appoints Bryce Szela as Chief Growth Officer - EIN News
Shoals Technologies Group, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and - EIN News
Equinix, Inc. (Nasdaq: EQIX) Investor Alert: Grabar Law Investigates Claims as Securities Fraud Class Action - EIN News
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update - EIN News
Silvercrest Asset Management Group Inc. Announces Quarterly Dividend - EIN News
Creative Medical Technology Holdings Inc Azioni (CELZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Creative Medical Technology Holdings Inc Azioni (CELZ) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Finger Michael H. | Director |
Feb 18 '25 |
Sale |
5.00 |
750 |
3,750 |
1,101 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):